The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts against Charles River Laboratories International, Inc. (“Charles River”) ((CRL). The action charges Charles River with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects. As a result of Charles River’s materially misleading statements and omissions to the public, Charles River’s investors have suffered significant losses.
CLICK HERE TO SUBMIT YOUR CHARLES RIVER LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://ift.tt/ibnA8RH
LEAD PLAINTIFF DEADLINE: JULY 18, 2023
CLASS PERIOD: MAY 5, 2020 THROUGH FEBRUARY 21, 2023
CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
Jonathan Naji, Esq. at (484) 270-1453 or via email at info@ktmc.com
Kessler Topaz is one of the world’s foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.
CHARLES RIVER’S ALLEGED MISCONDUCT
Charles River is a full-service, non-clinical global drug development partner with a mission to create healthier lives. The company has three reporting segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. The Discovery and Safety Assessment segment accounts for approximately 60% of the company’s total revenue and offers, among other things, safety assessment studies required…
The post Securities Class Action Reminder (NYSE: CRL): Kessler Topaz Meltzer & Check, LLP… – Press Release appeared first on CaymanMama.com.
from CaymanMama.com https://ift.tt/5WEDaBc
No comments:
Post a Comment